ScreenerHero

AQST Aquestive Therapeutics, Inc.

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · aquestive.com
4.620USD+0.22%Mkt Cap: 579.86M $P/E: —

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a su…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$66.23BUSDP/E 25.7
TAK
Takeda Pharmaceutical Company Limited
$58.68BUSD
TEVA
Teva Pharmaceutical Industries Limited
$45.70BUSDP/E 65.3
GALD
Galderma Group AG
$43.27BUSDP/E 56.1
HLN
Haleon plc
$39.67BUSDP/E 18.4
SDZ
Sandoz Group AG
$34.93BUSDP/E 60.5
HLN
Haleon plc
$32.73BUSDP/E 19.0
ZTS
Zoetis Inc.
$29.57BUSDP/E 11.8
ZOE
Zoetis Inc.
$28.56BUSDP/E 12.2
UTHR
United Therapeutics Corporation
$23.38BUSDP/E 19.5
VTRS
Viatris Inc.
$20.09BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.43BUSDP/E 112.9
NBIX
Neurocrine Biosciences, Inc.
$14.58BUSDP/E 21.0
IPN
Ipsen S.A.
$12.99BUSDP/E 23.5
ELAN
Elanco Animal Health Incorporated
$11.17BUSD
RDY
Dr. Reddy's Laboratories Limited
$10.22BUSDP/E 27.9
KRK
Krka, d. d.
$8.66BUSDP/E 19.3
ALKS
Alkermes plc
$6.95BUSDP/E 109.1
HIMS
Hims & Hers Health, Inc.
$6.89BUSD
AMRX
Amneal Pharmaceuticals, Inc.
$6.84BUSDP/E 40.1

Key Statistics

Company
Market Cap579.86M USD
Enterprise Value539.15M USD
Revenue (TTM)54.09M USD
Gross Profit25.99M USD
Net Income (TTM)-83.78M USD
Revenue/Share0.45 USD
Last Price4.620 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees147
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-8.09
PEG—
EV/EBITDA-10.33
EV/Revenue9.97
P/S10.70
P/B-10.22
EPS (TTM)-0.66
EPS (Forward)-0.57
52W Range
2.93037% of range7.550
52W High7.550 USD
52W Low2.930 USD
Profitability
Gross Margin58.35%
Oper. Margin-59.51%
EBITDA Margin-96.51%
Profit Margin-188.09%
ROE248.90%
ROA-52.23%
Growth
Revenue Growth38.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-52.43M USD
CapEx (TTM)562.00K USD
FCF Margin-49.72%
FCF Yield-4.64%
Net Debt-39.46M USD
Net Debt/EBITDA0.76
Balance Sheet
Debt/Equity-1.26
Current Ratio7.19
Quick Ratio6.54
Book Value/Sh-0.45 USD
Cash/Share0.79 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)9.333 USD
Upside (mean)+102.0%
Target Range6.000 USD – 11.00 USD
6.000+102.0% to mean11.00
# Analysts9
Ownership
Shares Out.125.51M
Float114.61M
Insiders2.77%
Institutions58.39%
Short Interest
Short Ratio9.1d
Short % Float22.65%
Short % Out.21.64%
Shares Short27.16M
Short (prev mo.)20.95M
Technical
SMA 504.575 (+1.0%)
SMA 2004.334 (+6.6%)
Beta1.49
S&P 52W Chg16.45%
Avg Vol (30d)2.48M
Avg Vol (10d)2.08M
Technical Indicators
RSI (14)48.2
MACD-0.0193
MACD Signal0.0265
MACD Hist.-0.0458
BB Upper5.157 USD
BB Middle4.760 USD
BB Lower4.363 USD
BB Width16.66%
ATR (14)0.2241 USD
Vol Ratio (20d)0.60x